Even as new evidence stacks up that traditional Chinese medicines, or TCMs, pose potential health risks, one such medicine has been authorized for sale in a European market for the first time.
The name of the medicine is Di'ao Xin Xue Kang, developed by Chengdu, China-based Di'ao Group, and the European market in which the TCM will make its debut is Netherlands. In China, the medicine has been sold since 1988 for treating heart disease.
Remember that EU has imposed a ban on non-European healthcare systems like traditional Chinese medicine, Tibetan medicine, Ayurveda, southern African, Amazonian and other traditions, which has been in effect since May 2011.
A new research study published April 12 in the journal Public Library of Science Genetics, noted that 15 TCM samples, seized by Australian Customs and Border Protection Service, in the form of powders, tablets, capsules, bile flakes, and herbal teas, when screened by DNA sequencing technology, revealed the presence of 68 different plant families, including genera, such as Ephedra and Asarum, that are potentially toxic, as well as endangered animal families like Asiatic black bear and Saiga antelope.
However, Chinese experts have reportedly said that the fears about the toxicity of traditional Chinese medicines are unfounded, "as the time-honored therapy is backed by developed theories and drug- making techniques".
The approval of Di'ao Xin Xue Kang as a therapeutic medicine by Medicines Evaluation Board of the Netherlands, paves way for the Chinese traditional medicine to enter the mainstream European market, say Chinese experts of the industry.
Is herbal medicine taking a root in Europe?
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org